India’s Sun Pharma raises Rs. 10 billion of non-convertible debentures

By Tali Rackner

Norfolk, Va., Dec. 24 – Sun Pharmaceutical Industries Ltd. informed the Bombay Stock Exchange that its wholly owned subsidiary, Sun Pharma Laboratories Ltd., raised Rs. 10 billion of funds through two issues of rated unsecured redeemable non-convertible debentures.

The debentures have a face value of Rs. 1 million each and were issued on a private placement basis.

The company issued 5,000 series 1 debentures with a tenor of 24 months and 5,000 series 2 debentures with a tenor of 39 months.

Sun Pharmaceuticals is a Mumbai-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.